Liver diagnosis company Echosens reported on Monday that it has received a MedTech Innovation Briefing (MIB) for the utilization of FibroScan liver non-invasive technology in the primary care setting from National Institute for Health and Care Excellence (NICE), the UK's health technology assessment body providing national guidance and advice to improve health and social care.

Non-alcoholic fatty liver disease (NAFLD) is a spectrum of the disease characterized by the accumulation of lipids in liver cells not associated with the consumption of alcohol. Its more severe form, non-alcoholic steatohepatitis (NASH) is an asymptomatic, progressive and burgeoning liver disease that can lead to increased liver-related mortality and morbidity.

NICE reportedly expects that the company's FibroScan Liver Exam could provide a cost-effective way for the National Health System (NHS) to assess liver fibrosis and cirrhosis in primary care. The panel of experts agreed that other technologies fail to offer the same benefits as FibroScan, which is highly portable, less expensive and requires minimal training time.

FibroScan is recognized worldwide as the reference for non-invasive liver fibrosis and liver steatosis assessment with more than 2,500+ peer reviewed publications and 60+ international guidelines recommendations. The company has launched FibroScan in over 100+ countries enabling millions of liver examinations worldwide.